Amendment: SEC Form SC 13G/A filed by Biogen Inc.

11/12/24 1:24:28 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BIIB alert in real time by email

SC 13G/A 1 UnitedStates_13G__BiogenIncU.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* (Name of Issuer) Biogen Inc (Title of Class of Securities) Common Stock (CUSIP Number) 09062X103 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 09062X103 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 179,337 (7) Sole dispositive power 16,033,598 (8) Shared dispositive power 644,208 (9) Aggregate amount beneficially owned by each reporting person 16,677,806 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 11.44% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Biogen Inc Item 1(b) Address of issuer's principal executive offices: 225 Binney Street Cambridge, MA 02142 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 09062X103 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 16,677,806 (b) Percent of class: 11.44% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 16,677,806 (b) Percent of class: 11.44% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 179,337 (iii) Sole power to dispose or to direct the disposition of: 16,033,598 (iv) Shared power to dispose or to direct the disposition of: 644,208 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

Get the next $BIIB alert in real time by email

Recent Analyst Ratings for

$BIIB

Date	Price Target	Rating	Analyst
4/28/2025	$118.00	Buy → Hold	HSBC Securities
4/4/2025		Buy → Hold	Argus
2/11/2025	$160.00	Mkt Perform	Bernstein
1/2/2025	$315.00 → $138.00	Overweight → Neutral	Piper Sandler
12/20/2024	$230.00 → $164.00	Outperform → Market Perform	BMO Capital Markets
12/16/2024	$175.00	Buy → Hold	Stifel
12/10/2024	$178.00	Neutral	BofA Securities
12/9/2024	$250.00 → $180.00	Buy → Hold	Jefferies

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Biogen Inc.

Chat with this insight

Recent Analyst Ratings for
$BIIB

$BIIB
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for VUMERITY issued to BIOGEN INC

FDA Approval for VUMERITY issued to BIOGEN INC

FDA Approval for VUMERITY issued to BIOGEN INC

$BIIB
Press Releases

Fastest customizable press release news feed in the world

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

$BIIB
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

$BIIB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Biogen downgraded by HSBC Securities with a new price target

Biogen downgraded by Argus

Bernstein initiated coverage on Biogen with a new price target

$BIIB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Pangalos Menelas N

Director Minor Lloyd was granted 2,370 shares (SEC Form 4)

Director Patolawala Monish D was granted 2,370 shares, increasing direct ownership by 177% to 3,710 units (SEC Form 4)

$BIIB
SEC Filings

SEC Form DEFA14A filed by Biogen Inc.

SEC Form 144 filed by Biogen Inc.

SEC Form 8-K filed by Biogen Inc.

$BIIB
Large Ownership Changes

This live feed shows all institutional transactions in real time.